Showing 1 - 7 results of 7 for search 'Huihui Mou', query time: 0.04s Refine Results
  1. 1
    Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2.

    Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2. by Tianling Ou, Huihui Mou, Lizhou Zhang, Amrita Ojha, Hyeryun Choe, Michael Farzan

    Published 2021-01-01
    Get full text
    Article
  2. 2
    Predicting the efficacy of COVID-19 convalescent plasma donor units with the Lumit Dx anti-receptor binding domain assay.

    Predicting the efficacy of COVID-19 convalescent plasma donor units with the Lumit Dx anti-receptor binding domain assay. by Sanath Kumar Janaka, Natasha M Clark, David T Evans, Huihui Mou, Michael Farzan, Joseph P Connor

    Published 2021-01-01
    Get full text
    Article
  3. 3
    SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity

    SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity by Lizhou Zhang, Cody B. Jackson, Huihui Mou, Amrita Ojha, Haiyong Peng, Brian D. Quinlan, Erumbi S. Rangarajan, Andi Pan, Abigail Vanderheiden, Mehul S. Suthar, Wenhui Li, Tina Izard, Christoph Rader, Michael Farzan, Hyeryun Choe

    Published 2020-11-01
    Get full text
    Article
  4. 4
    Engineering well-expressed, V2-immunofocusing HIV-1 envelope glycoprotein membrane trimers for use in heterologous prime-boost vaccine regimens.

    Engineering well-expressed, V2-immunofocusing HIV-1 envelope glycoprotein membrane trimers for use in heterologous prime-boost vaccine regimens. by Emma T Crooks, Francisco Almanza, Alessio D'Addabbo, Erika Duggan, Jinsong Zhang, Kshitij Wagh, Huihui Mou, Joel D Allen, Alyssa Thomas, Keiko Osawa, Bette T Korber, Yaroslav Tsybovsky, Evan Cale, John Nolan, Max Crispin, Laurent K Verkoczy, James M Binley

    Published 2021-10-01
    Get full text
    Article
  5. 5
    Engineering well-expressed, V2-immunofocusing HIV-1 envelope glycoprotein membrane trimers for use in heterologous prime-boost vaccine regimens

    Engineering well-expressed, V2-immunofocusing HIV-1 envelope glycoprotein membrane trimers for use in heterologous prime-boost vaccine regimens by Emma T. Crooks, Francisco Almanza, Alessio D’Addabbo, Erika Duggan, Jinsong Zhang, Kshitij Wagh, Huihui Mou, Joel D. Allen, Alyssa Thomas, Keiko Osawa, Bette T. Korber, Yaroslav Tsybovsky, Evan Cale, John Nolan, Max Crispin, Laurent K. Verkoczy, James M. Binley

    Published 2021-10-01
    Get full text
    Article
  6. 6
    Mutations derived from horseshoe bat ACE2 orthologs enhance ACE2-Fc neutralization of SARS-CoV-2.

    Mutations derived from horseshoe bat ACE2 orthologs enhance ACE2-Fc neutralization of SARS-CoV-2. by Huihui Mou, Brian D Quinlan, Haiyong Peng, Guanqun Liu, Yan Guo, Shoujiao Peng, Lizhou Zhang, Meredith E Davis-Gardner, Matthew R Gardner, Gogce Crynen, Lindsey B DeVaux, Zhi Xiang Voo, Charles C Bailey, Michael D Alpert, Christoph Rader, Michaela U Gack, Hyeryun Choe, Michael Farzan

    Published 2021-04-01
    Get full text
    Article
  7. 7
    Identification of potent small molecule inhibitors of SARS-CoV-2 entry

    Identification of potent small molecule inhibitors of SARS-CoV-2 entry by Sonia Mediouni, Huihui Mou, Yuka Otsuka, Joseph Anthony Jablonski, Robert Scott Adcock, Lalit Batra, Dong-Hoon Chung, Christopher Rood, Ian Mitchelle S. de Vera, Ronald Rahaim Jr., Sultan Ullah, Xuerong Yu, Yulia A. Getmanenko, Nicole M. Kennedy, Chao Wang, Tu-Trinh Nguyen, Mitchell Hull, Emily Chen, Thomas D. Bannister, Pierre Baillargeon, Louis Scampavia, Michael Farzan, Susana T. Valente, Timothy P. Spicer

    Published 2022-01-01
    Get full text
    Article

Search Tools: